Search

Your search keyword '"Tanner, Chloe"' showing total 7 results
Start Over Author "Tanner, Chloe"
7 results on '"Tanner, Chloe"'

1. Saliva antiviral antibody levels are detectable but correlate poorly with serum antibody levels following SARS-CoV-2 infection and/or vaccination

Author

Faustini, Siân E., Cook, Alex, Hill, Harriet, Al-Taei, Saly, Heaney, Jennifer, Efstathiou, Elena, Tanner, Chloe, Townsend, Neal, Ahmed, Zahra, Dinally, Mohammad, Hoque, Madeeha, Goodall, Margaret, Stamataki, Zania, Plant, Timothy, Chapple, Iain, Cunningham, Adam F., Drayson, Mark T., Shields, Adrian M., and Richter, Alex G.

Published
2023
Full Text
View/download PDF

2. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study

Author

Shields, Adrian M., Faustini, Sian E., Hill, Harriet J., Al-Taei, Saly, Tanner, Chloe, Ashford, Fiona, Workman, Sarita, Moreira, Fernando, Verma, Nisha, Wagg, Hollie, Heritage, Gail, Campton, Naomi, Stamataki, Zania, Klenerman, Paul, Thaventhiran, James E. D., Goddard, Sarah, Johnston, Sarah, Huissoon, Aarnoud, Bethune, Claire, Elcombe, Suzanne, Lowe, David M., Patel, Smita Y., Savic, Sinisa, Burns, Siobhan O., and Richter, Alex G.

Published
2022
Full Text
View/download PDF

3. Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals

Author

Faustini, Sian, Shields, Adrian, Banham, Gemma, Wall, Nadezhda, Al-Taei, Saly, Tanner, Chloe, Ahmed, Zahra, Efstathiou, Elena, Townsend, Neal, Goodall, Margaret, Plant, Tim, Perez-Toledo, Marisol, Jasiulewicz, Aleksandra, Price, Ruth, McLaughlin, James, Farnan, John, Moore, Julie, Robertson, Louise, Nesbit, Andrew, Curry, Grace, Black, Amy, Cunningham, Adam, Harper, Lorraine, Moore, Tara, Drayson, Mark, and Richter, Alex

Published
2022
Full Text
View/download PDF

4. Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD study

Author

Shields, Adrian M, primary, Faustini, Sian E., additional, Hill, Harriet J., additional, Al-Taei, Saly, additional, Tanner, Chloe, additional, Ashford, Fiona, additional, Workman, Sarita, additional, Moreira, Fernando, additional, Verma, Nisha, additional, Wagg, Hollie, additional, Heritage, Gail, additional, Campton, Naomi, additional, Stamataki, Zania, additional, Drayson, Mark T., additional, Klenerman, Paul, additional, Thaventhiran, James E. D., additional, Elkhalifa, Shuayb, additional, Goddard, Sarah, additional, Johnston, Sarah, additional, Huissoon, Aarnoud, additional, Bethune, Claire, additional, Elcombe, Suzanne, additional, Lowe, David M., additional, Patel, Smita Y., additional, Savic, Sinisa, additional, Richter, Alex G., additional, Burns, Siobhan O., additional, and Consortium, COVAD, additional

Published
2022
Full Text
View/download PDF

5. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings From The COV-AD Study

Author

Shields, Adrian M, primary, Faustini, Sian E., additional, Hill, Harriet J., additional, Al-Taei, Saly, additional, Tanner, Chloe, additional, Ashford, Fiona, additional, Workman, Sarita, additional, Moreira, Fernando, additional, Verma, Nisha, additional, Wagg, Hollie, additional, Heritage, Gail, additional, Campton, Naomi, additional, Stamataki, Zania, additional, Klenerman, Paul, additional, Goddard, Sarah, additional, Johnston, Sarah, additional, Huissoon, Aarnoud, additional, Bethune, Claire, additional, Elcombe, Suzanne, additional, Lowe, David M., additional, Patel, Smita Y., additional, Savic, Sinisa, additional, Burns, Siobhan O., additional, Richter, Alex G., additional, and Consortium, COV-AD, additional

Published
2022
Full Text
View/download PDF

6. Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose

Author

Faustini, Sian E, primary, Shields, Adrian M, additional, Banham, Gemma, additional, Wall, Nadezhda, additional, Al-Taei, Saly, additional, Tanner, Chloe, additional, Ahmed, Zahra, additional, Efstathiou, Elena, additional, Townsend, Neal, additional, Plant, Tim, additional, Perez-Toledo, Marisol, additional, Jasiulewicz, Aleksandra, additional, Price, Ruth, additional, McLaughlin, James, additional, Farnan, John, additional, Moore, Julie, additional, Robertson, Louise, additional, Nesbit, Andrew, additional, Curry, Grace, additional, Black, Amy, additional, Cunningham, Adam F, additional, Harper, Lorraine, additional, Moore, Tara, additional, Drayson, Mark T, additional, and Richter, Alex G, additional

Published
2022
Full Text
View/download PDF

7. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.

Author

Shields, Adrian M., Faustini, Sian E., Hill, Harriet J., Al-Taei, Saly, Tanner, Chloe, Ashford, Fiona, Workman, Sarita, Moreira, Fernando, Verma, Nisha, Wagg, Hollie, Heritage, Gail, Campton, Naomi, Stamataki, Zania, Drayson, Mark T., Klenerman, Paul, Thaventhiran, James E. D., Elkhalifa, Shuayb, Goddard, Sarah, Johnston, Sarah, and Huissoon, Aarnoud

Subjects
ANTIBODY formation, PRIMARY immunodeficiency diseases, SARS-CoV-2, COVID-19 vaccines, IMMUNIZATION
Abstract

Background: Patients with primary and secondary antibody deficiency are vulnerable to COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine schedules. Third primary vaccinations have been deployed to enhance their humoral and cellular immunity. Objectives: To determine the immunogenicity of the third primary SARS-CoV-2 immunisation in a heterogeneous cohort of patients with antibody deficiency. Methods: Participants enrolled in the COV-AD study were sampled before and after their third vaccine dose. Serological and cellular responses were determined using ELISA, livevirus neutralisation and ELISPOT assays. Results: Following a two-dose schedule, 100% of healthy controls mounted a serological response to SARS-CoV-2 vaccination, however, 38.6% of individuals with antibody deficiency remained seronegative. A third primary SARS-CoV-2 vaccine significantly increased anti-spike glycoprotein antibody seroprevalence from 61.4% to 76.0%, the magnitude of the antibody response, its neutralising capacity and induced seroconversion in individuals who were seronegative after two vaccine doses. Vaccine-induced serological responses were broadly cross-reactive against the SARS-CoV-2 B.1.1.529 variant of concern, however, seroprevalence and antibody levels remained significantly lower than healthy controls. No differences in serological responses were observed between individuals who received AstraZeneca ChAdOx1 nCoV-19 and Pfizer BioNTech 162b2 during their initial two-dose vaccine schedule. SARS-CoV-2 infectionnaive participants who had received a heterologous vaccine as a third dose were significantly more likely to have a detectable T cell response following their third vaccine dose (61.5% vs 11.1%). Conclusion: These data support the widespread use of third primary immunisations to enhance humoral immunity against SARS-CoV-2 in individuals with antibody deficiency. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results